LNCARSR and renal cell carcinoma: Moreover, Qu et al. [110] provided plasma-circulating lncARSR as an independent prognostic factor for RCC patients with sunitinib therapy, by comparing the elevated level of lncARSR in the pre-therapy plasma of RCC patients suffering from progressive disease during sunitinib treatment to patients without progressive disease.